ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.14) by 7.14 percent. This is a 15.38 percent decrease over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $150.000 thousand which beat the analyst consensus estimate of $149.000 thousand by 0.67 percent. This is a 32.13 percent decrease over sales of $221.000 thousand the same period last year.